Efficacy and safety of lenalidomide and dexamethasone as consolidation therapy and lenalidomide as maintenance therapy after autologous stem cell transplantation for newly diagnosed multiple myeloma
Phase 2
- Conditions
- Multiple myeloma
- Registration Number
- JPRN-UMIN000019918
- Lead Sponsor
- Gifu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
blank
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of complete response (CR) plus very good partial response (VGPR) after lenalidomide and dexamethasone as consolidation therapy
- Secondary Outcome Measures
Name Time Method (1) Rate of complete response plus very good partial response after lenalidomide as maintenance therapy (2) Safety: Hematological toxicity of grade 4, non-hematological toxicity of grade 3 to 4, and the secondary malignancy (3) Overall survival (4) Progression-free survival (the rate of patients who are not recognized as having progression or recurrence)